Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 8Skin Neoplasms 2Uveal Melanoma 1The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data 1Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Healthy Volunteer 1Healthy Adults 1Eye Neoplasms 1

Interventions

aldesleukin 9Interleukin-2 9Nivolumab 7fludarabine phosphate 6Dacarbazine 6Cyclophosphamide 6fludarabine 5Temozolomide 4Ipilimumab 4Fluorouracil 4montanide ISA 51 3Surveys and Questionnaires 3Semaxinib 3Radiotherapy 3Radiation 3Mohs Surgery 3Educational Status 3Cisplatin 3Allovectin-7 3zanolimumab 2talabostat 2sonidegib 2poly ICLC 2binimetinib 2Whole-Body Irradiation 2Vinblastine 2Vemurafenib 2Tacrolimus 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Skin Neoplasms × Peptides × Clear all
NCT00254397 2019-10-16

Melanoma Vaccine With Peptides and Leuprolide

M.D. Anderson Cancer Center

Phase 2 Completed
98 enrolled 11 charts
Dermatologic

Uveal Melanoma, Eye Neoplasms, Melanoma, Skin Neoplasms

NCT00923195 2015-10-28

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
4 enrolled 11 charts
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡